This compound is primarily utilized in the field of biomedical research, particularly in targeted protein degradation studies. It serves as a key component in the development of PROTACs (Proteolysis Targeting Chimeras), which are designed to selectively degrade disease-causing proteins. Its structure allows it to bind effectively to E3 ubiquitin ligase, facilitating the ubiquitination and subsequent degradation of specific target proteins. This application is especially valuable in cancer research, where it helps in understanding and potentially treating various forms of cancer by eliminating oncogenic proteins. Additionally, it is used in drug discovery to validate new therapeutic targets and explore novel treatment strategies.